- Home
- JAZZ vs TOL Comparison
JAZZ vs TOL Comparison
Compare JAZZ & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | TOL |
|---|---|---|
| Founded | 2003 | 1967 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 15.1B |
| IPO Year | 2007 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | TOL |
|---|---|---|
| Price | $248.75 | $153.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | ★ $217.57 | $164.44 |
| AVG Volume (30 Days) | 789.8K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | 4.43 | ★ 4.91 |
| Revenue | $1,618,693,000.00 | ★ $7,143,258,000.00 |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $7.68 | $6.01 |
| P/E Ratio | $54.80 | ★ $31.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $116.53 |
| 52 Week High | $250.49 | $168.36 |
Technical Indicators
Market Signals| Indicator | JAZZ | TOL |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 53.09 |
| Support Level | $222.49 | $127.05 |
| Resistance Level | $250.49 | $167.30 |
| Average True Range (ATR) | 7.32 | 4.44 |
| MACD | 0.01 | -0.75 |
| Stochastic Oscillator | 89.13 | 41.08 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.